Effect of ketoacetate aminobutanol prophylactic analgesia on pbmc and postoperative recovery quality in colorectal cancer patients.
Ontology highlight
ABSTRACT:
DISEASE(S): Colorectal Cancer
PROVIDER: 2687132 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:Brain and Genetic Predictors of Placebo Analgesia
| PRJNA671312 | ENA
Project description:Brain and Genetic Predictors of Placebo Analgesia
| PRJNA671307 | ENA
Project description:This is a blinded randomized controlled trial in patients undergoing laparoscopic colon surgery. The aim of this study is to assess whether spinal analgesia with a mixture of bupivacaine and morphine provides better pain relief than systemic morphine in a group of patients undergoing colonic resection and using the Enhanced Recovery After Surgery (ERAS) program.
Twenty patients will receive spinal analgesia and twenty patients will receive only Patient Control Analgesia (PCA).
| 2116089 | ecrin-mdr-crc
Project description:Interventions: Group 1:0.25% ropivacaine was given 60mL bilateral RSB(20mL)+TAPB(40mL), and normal saline was injected with 10mL intravenous pump for 1h;Group 2:0.8ug/kg dexmedetomidine was added with 0.25% ropivacaine for 60mL of bilateral RSB+TAPB, and normal saline was injected with 10mL intravenous pump for 1h;Group 3:In the same control group, dexmedetomidine was diluted with 0.8ug/kg to 10mL and intravenously pumped for 1h
Primary outcome(s): QoR-40;NLR
Study Design: Parallel
| 2699496 | ecrin-mdr-crc
Project description:Sickle cell disease is the most common genetic disorder in African-Americans. The opioid analgesic, morphine, has long been the treatment for the severe pain associated with this disease. Here we reveal that the opioid antagonist, naloxone, possesses potent analgesic activity in two strains of sickle cell mice (NY1DD and hBERK1) and not in their respective controls (ICR-CD1 and C57BL/6J) when administered by three parenteral routes. In the NY1DD sickle mice, naloxone (i.c.v.) possessed ~300-fold greater potency than morphine (i.c.v.). Other opioid antagonists (naltrexone, norbinaltorphimine, naltrindole) were substantially less effective in producing analgesia. Naloxone and morphine were synergistic in NY1DD mice, suggesting that analgesia was mediated via different receptor systems. Since microarray analysis suggested naloxone-induced down-regulation of the CCR5 chemokine receptor in NY1DD mice but not in control mice, the role of its endogenous ligand, CCL5 (RANTES), was investigated. Keywords: Comparison of drug induced gene expression
2007-12-20 | GSE6479 | GEO
Project description:Gene expression in histologically normal epithelium from breast cancer patients and cancer-free prophylactic mastectomy patients share a similar profile Introduction: We hypothesized that gene expression in histologically normal epithelium (NlEpi) would differ in breast cancer patients (HN) compared to usual-risk controls undergoing reduction mammoplasty (RM), and that gene expression in NlEpi from cancer-free prophylactic mastectomies from high-risk women (PM), would resemble HN gene expression. Methods: We analyzed gene expression in 73 NlEpi samples microdissected from frozen tissue. In 42 cases, we used Affymetrix HU133A microarrays to compare gene expression in 18 RM vs 18 age-matched HN (9 ER+, 9 ER-) and 6 PM. Data were validated with qPCR in 31 independent NlEpi samples (8 RM, 17 HN, 6 PM). Results: 98 probesets (86 genes) were differentially expressed between RM and HN samples. Perfoming supervised hierarchical analysis with these 98 probesets, PM and HN samples clustered together, away from RM samples. qPCR validation of independent samples was high (84%) and uniform in RM vs HN, and lower (58%), but more heterogeneous, in RM vs PM. The 86 genes were implicated in many processes including transcription and the MAPK pathway. Conclusion: Gene expression differs between NlEpi of cancer cases and controls. The cancer cases' profile can be discerned in high-risk NlEpi. This suggests that the profile is not an effect of the tumor, but may mark increased risk and reveal breast cancer's earliest genomic changes. We determined that 98 probesets significantly differed between reduction mammoplasty and histologically normal epithelium from breast cancer patients. We also found that the histologically normal epithelium from prophylactic mastectomy patients' gene expression was more similar to histologically normal epithelium from breast cancer patients' than to reduction mammoplasty patients' gene expression. These results demonstrate that gene expression differs between NlEpi of cancer cases and controls. The cancer casesâ?? profile can be discerned in high-risk NlEpi. This suggests that the profile is not an effect of the tumor, but may mark increased risk and reveal breast cancer's earliest genomic changes. 42 total laser capture microdissected histologically normal breast tissue samples were analyzed with Affymetrix HU133A microarrays. 36 samples were age-matched between reduction mammoplasty (n=18) and histologically normal epithelial samples from breast cancer patients (n=18; 9ER+, 9ER-). 6 histologically normal epithelial samples from prophylactic mastectomy patients were then compared to data generated from the original 36 sample comparison. Sample numbers correspond to individual patient samples.
2010-06-08 | E-GEOD-20437 | biostudies-arrayexpress
Project description:This is a double blinded randomized controlled trial in patients undergoing colon open surgery. The purpose is to evaluate the effectiveness of two different analgesic techniques on functional recovery after surgery.
Twenty five patients will receive thoracic epidural analgesia plus patient controlled analgesia (PCA) (epidural analgesia group) and 25 patients wound infiltration of local anesthetic plus PCA (wound infusion group).
Hypothesis: the postoperative recovery of patients receiving local anesthetic wound infusion will be faster than patients receiving thoracic epidural analgesia.
Functional recovery, pain intensity, opioid consumption and side effects, length of hospital stay and biological markers of inflammation after surgery will be measured in both groups.
| 2084490 | ecrin-mdr-crc
Project description:Sickle cell disease is the most common genetic disorder in African-Americans. The opioid analgesic, morphine, has long been the treatment for the severe pain associated with this disease. Here we reveal that the opioid antagonist, naloxone, possesses potent analgesic activity in two strains of sickle cell mice (NY1DD and hBERK1) and not in their respective controls (ICR-CD1 and C57BL/6J) when administered by three parenteral routes. In the NY1DD sickle mice, naloxone (i.c.v.) possessed ~300-fold greater potency than morphine (i.c.v.). Other opioid antagonists (naltrexone, norbinaltorphimine, naltrindole) were substantially less effective in producing analgesia. Naloxone and morphine were synergistic in NY1DD mice, suggesting that analgesia was mediated via different receptor systems. Since microarray analysis suggested naloxone-induced down-regulation of the CCR5 chemokine receptor in NY1DD mice but not in control mice, the role of its endogenous ligand, CCL5 (RANTES), was investigated. Keywords: Comparison of drug induced gene expression
2007-03-14 | GSE6578 | GEO
Project description:Long-lasting Analgesia via Targeted in situ Repression of NaV1.7
| PRJNA670519 | ENA
Project description:Interventions: Patient-controlled intravenous analgesia group (PCIA group):Intravenous analgesia was used. The analgesic formula was sufentanil 200ug+ Ondansetron 8mg, with a total capacity of 100ml;Ultrasound-guided transabdominal muscle plane block with high concentration group (TAP5 group):An ultrasound-guided transversal plane block was performed on both sides, with each side injected with 0.5% ropivacaine (AstraZeneca, UK) 15ml;Ultrasound-guided erector spinae plane blcok with high concentration group (ESPB5 group):An ultrasound-guided vertical spinal muscle plane block was performed on both sides, each side was injected with 0.5% ropivacaine (AstraZeneca, UK) 15ml;High concentration group of epidural block analgesia (EB5 group):An epidural puncture was performed between T7-T8 and an injection of 0.5% ropivacaine (AstraZeneca, UK) 7ml was performed;Ultrasound-guided transabdominal muscle plane block with low concentration group (TAP3 group):An ultrasound-guided transversal plane block was performed on both sides, and 0.3% ropivacaine (AstraZeneca, UK) 15ml was injected on each side;Ultrasound-guided erector spinae plane block with low concentration group (ESPB3 group):An ultrasound-guided erector spinae plane block was performed on both sides, with each side at the T8 transverse process level. And 0.3% ropivacaine (AstraZeneca, UK) was injected with 15ml;Epidural block analgesia with low concentration group (EB3 group):The epidural puncture was performed between T8-T9 and injected with 0.3% ropivacaine (AstraZeneca, UK) 7ml;Combined with dexmedetomidine for ultrasound-guided transabdominal muscle plane block group (TAPDEX group):An ultrasound-guided transversal muscle plane block was performed on both sides, with 0.5% ropivacaine (AstraZeneca, UK) and 15ml of dexmedetomidine mixe
Primary outcome(s): Postoperative pain intensity score;Indicators related to inflammatory response;Indicators related to immune function
Study Design: Parallel
| 2696553 | ecrin-mdr-crc